December 21, 2021

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

December 6, 2021

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

November 15, 2021

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 8, 2021

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

November 8, 2021

TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021

November 5, 2021

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

October 28, 2021

TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19

October 14, 2021

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

September 23, 2021

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

September 8, 2021

TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference